[1] |
舒薇, 刘宇红. 世界卫生组织《2023年全球结核病报告》解读. 结核与肺部疾病杂志, 2024, 5 (1): 15-19. doi:10.19983/j.issn.2096-8493.2024006.
|
[2] |
Günther G, Ruswa N, Keller PM. Drug-resistant tuberculosis: advances in diagnosis and management. Curr Opin Pulm Med, 2022, 28(3): 211-217. doi:10.1097/MCP.0000000000000866.
pmid: 35220372
|
[3] |
Berry C, du Cros P, Fielding K, et al. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase Ⅱ-Ⅲ trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis. Trials, 2022, 23(1): 484. doi:10.1186/s13063-022-06331-8.
|
[4] |
World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization, 2020.
|
[5] |
Alsayed SSR, Gunosewoyo H. Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets. Int J Mol Sci, 2023, 24(6):5202. doi:10.3390/ijms24065202.
|
[6] |
Gao M, Gao J, Xie L, et al. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study. Clin Microbiol Infect, 2021, 27(4): 597-602. doi:10.1016/j.cmi.2020.06.004.
|
[7] |
Conradie F, Bagdasaryan TR, Borisov S, et al. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. N Engl J Med, 2022, 387(9): 810-823. doi:10.1056/NEJMoa2119430.
|
[8] |
Yang M, Zhan S, Fu L, et al. Prospects of contezolid (MRX-I) against multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Drug Discov Ther, 2022, 16(2):99-101. doi:10.5582/ddt.2022.01025.
pmid: 35418550
|
[9] |
Tiemersma EW, van der Werf MJ, Borgdorff MW, et al. Natu-ral history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS One, 2011, 6(4): e17601. doi:10.1371/journal.pone.0017601.
|
[10] |
马玉全, 周俊, 周爱平, 等. 非劣效试验中对照的选择和界值确定方法. 中国临床药理学与治疗学, 2009, 14(9): 961-965.
|
[11] |
Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med, 2012, 367(16):1508-1518. doi:10.1056/NEJMoa1201964.
|
[12] |
Sarin R, Vohra V, Singla N, et al. Early efficacy and safety of Bedaquiline and Delamanid given together in a “Salvage Regimen” for treatment of drug-resistant tuberculosis. Indian J Tuberc, 2019, 66(1): 184-188. doi:10.1016/j.ijtb.2019.02.006.
|
[13] |
Wang C, Wang G, Huo F, et al. Novel oxazolidinones harbor potent in vitro activity against the clinical isolates of multidrug-resistant Mycobacterium tuberculosis in China. Front Med (Lausanne), 2022, 9:1067516. doi:10.3389/fmed.2022.1067516.
|
[14] |
Wang J, Nie W, Ma L, et al. Clinical Utility of Contezolid-Containing Regimens in 25 Cases of Linezolid-Intolerable Tuberculosis Patients. Infect Drug Resist, 2023, 16: 6237-6245. doi:10.2147/IDR.S425743.
pmid: 37745897
|
[15] |
Wen S, Jing W, Zhang T, et al. Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis. Eur J Clin Microbiol Infect Dis, 2019, 38(7):1293-1296. doi:10.1007/s10096-019-03551-w.
|